首页 | 本学科首页   官方微博 | 高级检索  
检索        


Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database
Institution:1. Juravinski Cancer Center, Hamilton, Ontario, Canada;2. Canadian Myeloma Research Group, Toronto, Ontario, Canada;3. Princess Margaret Cancer Centre, Toronto, Ontario, Canada;4. The Ottawa Hospital, Ottawa, Ontario, Canada;5. Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada;6. BC Cancer Agency, Vancouver General Hospital, British Columbia, Canada;7. London Regional Cancer Center, London, Ontario, Canada;8. Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada;9. McGill University, Montreal, Quebec, Canada;10. Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia, Canada;11. Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada;12. Saint John Regional Hospital, Saint John, New Brunswick, Canada;13. Cancer Care Manitoba, Winnipeg, Manitoba, Canada;14. Allan Blair Cancer Centre, Regina, Saskatchewan, Canada;15. Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada;1. University of Health Science Izmir Bozyaka Training and Research Hospital, Department of Hematology, ?zmir, Turkey;2. Ankara University School of Medicine, Department of Hematology, Ankara, Turkey;3. Medicana International Ankara Hospital, Department of Hematology, Ankara, Turkey;1. Department of Pharmacy, Boston Medical Center, Boston, MA;2. School of Medicine, Boston University, Boston, MA;3. Department of Hematology and Oncology, Boston Medical Center, Boston, MA;1. University of South Florida, Morsani College of Medicine, Department of Internal Medicine. Tampa, FL;2. H. Lee Moffitt Cancer Center & Research Institute, Department of Malignant Hematology. Tampa, FL;1. Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL;2. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL;3. Department of pathology, Mayo Clinic, Jacksonville, FL;4. Department of Radiology, Mayo Clinic, Rochester, MN;5. Division of Hematology, Mayo Clinic, Rochester, MN;1. Department of Hematology and Medical Oncology, University of South Florida/ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;2. Morsani College of Medicine, University of South Florida, Tampa, FL;3. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;4. Department of Bone Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;5. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Abstract:BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally.
Keywords:MM"}  {"#name":"keyword"  "$":{"id":"pc_ouiHOwId6p"}  "$$":[{"#name":"text"  "_":"Multiple myeloma  ASCT"}  {"#name":"keyword"  "$":{"id":"pc_2ZIEzzRJoZ"}  "$$":[{"#name":"text"  "_":"Autologous stem cell transplant  TTNT"}  {"#name":"keyword"  "$":{"id":"pc_ybO5Jmp6Aq"}  "$$":[{"#name":"text"  "_":"Time to next treatment  PI"}  {"#name":"keyword"  "$":{"id":"pc_RZoqa5MX3U"}  "$$":[{"#name":"text"  "_":"Proteosome Inhibitor  IMiD"}  {"#name":"keyword"  "$":{"id":"pc_Q8vHz19RgB"}  "$$":[{"#name":"text"  "_":"Immunomodulatory drug
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号